Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

CGTX

C

Cognition Therapeutics, Inc. (CGTX)

NCM – Real Time Price. Currency in USD

0.73

-0.35 (-32.40%)

At close: Mar 27, 2026, 4:00 PM EDT

0.74

+0.01 (2.00%)

After-hours: Mar 27, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open.

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment.

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies.

Videos

No Data

There is no data to display

Press releases

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment.